206 related articles for article (PubMed ID: 31140295)
1. Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach.
Ongaro A; Zagotto G; Memo M; Gianoncelli A; Ribaudo G
Nat Prod Res; 2021 May; 35(10):1648-1653. PubMed ID: 31140295
[TBL] [Abstract][Full Text] [Related]
2. Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction.
Hudwekar AD; Kotwal P; Dar MI; Balgotra S; Dogra A; Kour J; Chobe SS; Nandi U; Hussain Syed S; Sawant SD
Chem Biodivers; 2023 Apr; 20(4):e202200707. PubMed ID: 36915218
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
[TBL] [Abstract][Full Text] [Related]
4. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
[TBL] [Abstract][Full Text] [Related]
5. Pyrazolopyrimidines in 'all-natural' products for erectile dysfunction treatment: the unreliable quality of dietary supplements.
Schramek N; Wollein U; Eisenreich W
Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2015; 32(2):127-40. PubMed ID: 25517174
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
Corbin JD; Francis SH; Webb DJ
Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Scaglione F; Donde S; Hassan TA; Jannini EA
Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
[TBL] [Abstract][Full Text] [Related]
8. Structural Determination, Biological Function, and Molecular Modelling Studies of Sulfoaildenafil Adulterated in Herbal Dietary Supplement.
Kodchakorn K; Viriyakhasem N; Wongwichai T; Kongtawelert P
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670094
[TBL] [Abstract][Full Text] [Related]
9. Discovery of two novel hetero-tricyclic lead scaffolds as PDE5A inhibitor: virtual screening, molecular docking and pharmacophore modeling approach.
Mali DP; Bhatia NM
Nat Prod Res; 2021 Jan; 35(1):92-98. PubMed ID: 31137981
[TBL] [Abstract][Full Text] [Related]
10. PDE5 inhibitors and their applications.
Giovannoni MP; Vergelli C; Graziano A; Dal Piaz V
Curr Med Chem; 2010; 17(24):2564-87. PubMed ID: 20491634
[TBL] [Abstract][Full Text] [Related]
11. Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5.
Chau Y; Li FS; Levsh O; Weng JK
PLoS One; 2019; 14(9):e0222803. PubMed ID: 31539416
[TBL] [Abstract][Full Text] [Related]
12. Adulteration of purported herbal and natural sexual performance enhancement dietary supplements with synthetic phosphodiesterase type 5 inhibitors.
Campbell N; Clark JP; Stecher VJ; Thomas JW; Callanan AC; Donnelly BF; Goldstein I; Kaminetsky JC
J Sex Med; 2013 Jul; 10(7):1842-9. PubMed ID: 23634714
[TBL] [Abstract][Full Text] [Related]
13. [Optimization of the use of phosphodiesterase-5 inhibitors].
Pushkar' DIu; Segal AS
Urologiia; 2012; (4):79-80, 82. PubMed ID: 23116030
[No Abstract] [Full Text] [Related]
14. Relaxant effects of selected sildenafil analogues in the rat aorta.
Mojzych M; Kubacka M; Mogilski S; Filipek B; Fornal E
J Enzyme Inhib Med Chem; 2016; 31(3):381-8. PubMed ID: 25798686
[TBL] [Abstract][Full Text] [Related]
15. Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.
Kayık G; Tüzün NŞ; Durdagi S
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):311-330. PubMed ID: 28150511
[TBL] [Abstract][Full Text] [Related]
16. Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
Houslay MD
Trends Cancer; 2016 Apr; 2(4):163-165. PubMed ID: 28741569
[TBL] [Abstract][Full Text] [Related]
17. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.
Samidurai A; Xi L; Das A; Kukreja RC
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():585-615. PubMed ID: 36206989
[TBL] [Abstract][Full Text] [Related]
18. Aphrodisiac Performance of Bioactive Compounds from
Palanichamy C; Pavadai P; Panneerselvam T; Arunachalam S; Babkiewicz E; Ram Kumar Pandian S; Shanmugampillai Jeyarajaguru K; Nayak Ammunje D; Kannan S; Chandrasekaran J; Sundar K; Maszczyk P; Kunjiappan S
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744923
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
20. Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds' repositories: biological evaluation.
Tömöri T; Hajdú I; Barna L; Lorincz Z; Cseh S; Dormán G
Mol Divers; 2012 Feb; 16(1):59-72. PubMed ID: 21947759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
